Baxter International reported third-quarter 2024 sales of $3.85 billion, with U.S. GAAP diluted earnings per share (EPS) of $0.27 and adjusted EPS of $0.80, surpassing prior guidance. However, the company has cut its annual profit forecast due to disruptions from a hurricane affecting its intravenous solutions facility in North Carolina. This announcement led to a 3.3% decline in Baxter's shares during premarket trading. The impact of the hurricane is expected to affect financials through early 2025, as Baxter warned of potential ongoing disruptions. Additionally, the company reported a non-GAAP EPS of $0.49 and revenue of $2.7 billion for the quarter. The overall market response reflects concerns about the company's future performance amid these challenges.